Psyence Biomedical Ltd (PBM) Stock Price, Quote & News

Company Profile

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress dis...

Industry: Biotechnology

Sector: Healthcare

Phone: 416 346 7764

Website: www.psyencebiomed.com

Address:

121 Richmond Street West, Penthouse Suite, 1300, Toronto, Canada

encostock Oct. 25 at 9:28 AM

$PBM confirmed cash 11 5 milion in August?

1 · Reply

LowFloatScanner_ Oct. 24 at 8:32 PM

What is happening to ticker CMCT right now?! CMCT is breaking out like crazy.. Are they pumping up ticker CMCT for 300% today!? Its insane what's going on in this market.. Looks like all eyes are moving to CMCT now.. Watching: $LASE $APVO $PBM $RAYA splits

0 · Reply

Neggudgid Oct. 24 at 4:39 PM

$PBM Man this thing needs news BAD!!

0 · Reply

Tradetime3472 Oct. 24 at 3:22 AM

$PBM https://cen.acs.org/biological-chemistry/magic-mushrooms-psilocybin/103/web/2025/10

0 · Reply

MyPreciousShares Oct. 23 at 12:31 AM

$PBM someone had a rush to load up in AH - 5149 shares traded last 10 mins. That’s the 3rd highest volume candle on the day. Forced the share price up 5%

1 · Reply

Bubbasoup09 Oct. 22 at 4:50 PM

$PBM this one got stuck on a bad trip! Check back in a couple weeks…

0 · Reply

stocktwitsaccount69 Oct. 20 at 6:07 PM

$PBM any info on this offering with white lion?

1 · Reply

Neggudgid Oct. 20 at 12:08 PM

$PBM Time to strike up the band.

0 · Reply

Bubbasoup09 Oct. 20 at 1:16 AM

$PBM 4hr/ Daily charts look good. Got stepped down from 4.20 > 3.50 on ~5k shares. Held up in the 3.50 range last week. White Lion will need to generate volume for offering. Still preliminary. Still bullish here. Would like to see 3.80 end of week. Below 3.30 is probably a cut for me.

0 · Reply

DriuxP Oct. 17 at 7:49 PM

$ATAI $MNMD excellent performances out of these two today. $CMPS $PSIL $PBM

0 · Reply

Psyence BioMed to Present at the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025

Jul 31, 2025, 7:30 AM EDT - 3 months ago

Psyence BioMed's Strategic Collaboration with PsyLabs Yields Breakthrough in High-Purity Ibogaine Production

Jun 25, 2025, 5:00 PM EDT - 4 months ago

PSYENCE GROUP INC. Announces Update on Previously Announced Non-Brokered Private Placement of Common Shares

Jun 18, 2025, 5:36 PM EDT - 4 months ago

PSYENCE GROUP INC. Announces Offering of up to C$600,000 Non-Brokered Private Placement of Common Shares

Jun 18, 2025, 8:30 AM EDT - 4 months ago

Psyence BioMed Chief of Global Impact to Speak at Psychedelic Science 2025

Jun 17, 2025, 8:00 AM EDT - 4 months ago

Psyence Biomed Regains Full Compliance with NASDAQ Continued Listing Requirements

May 27, 2025, 7:30 AM EDT - 5 months ago

Psyence BioMed Finalizes Agreement with Award-Winning CRO Southern Star Research to Accelerate Phase IIb Clinical Trial

May 1, 2025, 7:30 AM EDT - 6 months ago

Psyence BioMed Announces Effective Date for 1-for-7.97 Reverse Stock Split

Apr 17, 2025, 7:17 PM EDT - 6 months ago

Psyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Apr 17, 2025, 9:39 AM EDT - 6 months ago

Psyence Group Announces Share Consolidation

Apr 15, 2025, 8:30 AM EDT - 6 months ago

Psyence BioMed Announces USD$500,000 Follow-On Investment in PsyLabs and Global Ibogaine Supply Agreement

Apr 8, 2025, 8:00 AM EDT - 7 months ago

Psyence BioMed Signs LOI with Southern Star Research to Expand Phase IIb Clinical Trial in Australia

Mar 31, 2025, 8:00 AM EDT - 7 months ago

Corporate Update: Psyence Biomedical Ltd Redefines Psychedelic Medicine with a Multi-Asset Strategy, Advancing Clinical Trials and Scalable Manufacturing

Mar 18, 2025, 8:30 AM EDT - 7 months ago

Psyence Biomed Further Strengthens Scientific Advisory Board with Appointment of Dr. Dan J. Stein

Mar 10, 2025, 11:18 AM EDT - 8 months ago

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D.

Feb 26, 2025, 8:00 AM EST - 8 months ago

Psyence Biomed Names Albert P. Garcia-Romeu, Ph.D.

Dec 27, 2024, 4:05 PM EST - 10 months ago

Psyence Biomed Announces Closing of $2.0 Million Private Placement

Dec 23, 2024, 7:30 AM EST - 10 months ago

Psyence Biomedical Regains Full Compliance with All Nasdaq Continued Listing Requirements

Dec 17, 2024, 8:37 AM EST - 11 months ago

Psyence Biomed Highlights Recent Progress on Active Phase IIb Clinical Trial

Dec 17, 2024, 7:30 AM EST - 11 months ago

Optimi Health to Supply GMP-Certified Psilocybin for Psyence Biomed's Phase IIb Palliative Care Trial

Dec 10, 2024, 7:30 AM EST - 11 months ago

Psyence Biomed Executes Binding Agreements with Optimi Health Corp.

Dec 6, 2024, 11:06 AM EST - 11 months ago

Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligations

Dec 3, 2024, 7:30 AM EST - 11 months ago

Psyence Biomedical Issues Shareholder Update Highlighting Recent Progress

Nov 19, 2024, 4:05 PM EST - 1 year ago

Psyence Biomedical Announces Effective Date for 1-for-75 Share Consolidation

Nov 12, 2024, 4:30 PM EST - 1 year ago

Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq

Oct 31, 2024, 9:30 AM EDT - 1 year ago

Psyence Group Announces Closing of Previously Announced Disposal of its Stake in PsyLabs

Oct 25, 2024, 9:42 AM EDT - 1 year ago

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care

Oct 24, 2024, 7:00 AM EDT - 1 year ago

Psyence Biomed Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care

Oct 17, 2024, 7:00 AM EDT - 1 year ago

Psyence Biomed Provides Progress Update on PsyLabs E.U. Good Manufacturing Practices (GMP) Certified Active Pharmaceutical Ingredient (API) Development

Oct 14, 2024, 10:43 AM EDT - 1 year ago

Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical

Oct 4, 2024, 4:05 PM EDT - 1 year ago

Psyence Biomed Provides Update on Previously Announced Acquisition of Clairvoyant

Sep 20, 2024, 11:20 AM EDT - 1 year ago

Psyence Group Enters into Agreement to Dispose of Stake in PsyLabs

Sep 19, 2024, 7:30 AM EDT - 1 year ago

Psyence Biomed Enters into Agreement to Acquire Stake in PsyLabs

Sep 18, 2024, 9:30 AM EDT - 1 year ago

Psyence Group's NASDAQ-Listed Associate, Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones

Sep 16, 2024, 9:31 AM EDT - 1 year ago

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care

Sep 16, 2024, 7:30 AM EDT - 1 year ago

Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones

Sep 13, 2024, 4:30 PM EDT - 1 year ago

Psyence Biomedical Ltd. Announces Receipt of Staff Delisting Determination from Nasdaq

Sep 9, 2024, 7:30 AM EDT - 1 year ago

Psyence Biomed Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care

Sep 6, 2024, 7:30 AM EDT - 1 year ago

Psyence Biomed Announces the Signing of a Conditional Binding Term Sheet for the Acquisition of Psilocybin-Based Drug Developer Clairvoyant

Aug 30, 2024, 7:00 AM EDT - 1 year ago

Psyence Biomed Announces Registration Statement on Form F-1 for Up to $25 Million Equity Line of Credit with White Lion Capital, LLC, Declared Effective by SEC

Aug 27, 2024, 4:05 PM EDT - 1 year ago

Psyence Biomed to Present at the H.C. Wainwright 26th Annual Global Investment Conference, September 9th-11th, 2024

Aug 13, 2024, 7:30 AM EDT - 1 year ago

Optimi Health and Psyence Biomedical Sign Non-Binding Letter of Intent to Advance Global Psilocybin Drug Development

Jul 31, 2024, 4:05 PM EDT - 1 year ago

Psyence Biomed Enters Into $25 Million Common Stock Purchase Agreement with White Lion Capital, LLC

Jul 26, 2024, 9:30 AM EDT - 1 year ago

Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial

Jul 24, 2024, 4:05 PM EDT - 1 year ago

Psyence Biomed Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial

Jul 3, 2024, 8:34 PM EDT - 1 year ago

Psyence Biomedical Ltd. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

May 17, 2024, 7:00 AM EDT - 1 year ago

Psyence Biomed to Participate in the A.G.P. Virtual Healthcare Company Showcase

Apr 17, 2024, 8:00 AM EDT - 1 year ago

Psyence Biomed Announces Phase IIb Clinical Trial Listing on the Australian New Zealand Clinical Trials Registry (ANZCTR)

Apr 16, 2024, 11:01 AM EDT - 1 year ago

Psyence Group's NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial

Apr 8, 2024, 8:00 AM EDT - 1 year ago

Psyence Biomed Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial

encostock Oct. 25 at 9:28 AM

$PBM confirmed cash 11 5 milion in August?

1 · Reply

LowFloatScanner_ Oct. 24 at 8:32 PM

0 · Reply

Neggudgid Oct. 24 at 4:39 PM

$PBM Man this thing needs news BAD!!

0 · Reply

Tradetime3472 Oct. 24 at 3:22 AM

$PBM https://cen.acs.org/biological-chemistry/magic-mushrooms-psilocybin/103/web/2025/10

0 · Reply

MyPreciousShares Oct. 23 at 12:31 AM

$PBM someone had a rush to load up in AH - 5149 shares traded last 10 mins. That’s the 3rd highest volume candle on the day. Forced the share price up 5%

1 · Reply

Bubbasoup09 Oct. 22 at 4:50 PM

$PBM this one got stuck on a bad trip! Check back in a couple weeks…

0 · Reply

stocktwitsaccount69 Oct. 20 at 6:07 PM

$PBM any info on this offering with white lion?

1 · Reply

Neggudgid Oct. 20 at 12:08 PM

$PBM Time to strike up the band.

0 · Reply

Bubbasoup09 Oct. 20 at 1:16 AM

0 · Reply

DriuxP Oct. 17 at 7:49 PM

$ATAI $MNMD excellent performances out of these two today. $CMPS $PSIL $PBM

0 · Reply

themaestro420 Oct. 16 at 6:10 PM

$PBM I think Rogan has brought up ibogaine on the last 8 podcasts😂 he needs to get RFKs ear more lol

0 · Reply

Tradetime3472 Oct. 16 at 2:55 PM

$PBM https://www.latimes.com/california/story/2025-10-16/newsom-signs-veteran-backed-bill-to-accelerate-study-of-psychedelics-for-ptsd-mental-health

0 · Reply

RuddyRolls Oct. 16 at 2:35 PM

$PBM wen data

0 · Reply

BioBum Oct. 16 at 11:03 AM

$PBM they aren’t even in phase 1 yet with ibogaine? Just think this is a cool idea so far. Don’t have a lot of capital. You wonder why the big names haven’t started or restarted their ibogaine?

1 · Reply

Tradetime3472 Oct. 15 at 9:53 PM

$PSIL currently $PBM is their smallest holdings. Be on the watch out though they are most likely going to start increasing it as PBM releases more PRs on their nature derived ibogaine asset

0 · Reply

Tradetime3472 Oct. 15 at 8:02 PM

$PBM https://www.marijuanamoment.net/va-official-says-federal-government-must-gear-up-for-expanding-psychedelic-medicine-for-veterans/

0 · Reply

DriuxP Oct. 15 at 4:51 PM

$PSIL $ATAI $CMPS $MNMD $PBM as a longtime daily medicinal user, cannabis is decent for mental health, but imo closer to a band-aid more than anything. There are other companies that will be developing the real solutions for mental health. Holding and bullish on both canna and psych but I don't expect cannabis to change my life, from a mental health or financial standpoint.

0 · Reply

AKnewMann Oct. 15 at 1:52 PM

$PBM nice daily candle showing up. Looks primed for another big run

0 · Reply

Vynfred Oct. 14 at 9:25 PM

$PBM Just found this from the ATAI board... shill me, new CEO it seems? Bullish on the sector overall.

1 · Reply

Tradetime3472 Oct. 14 at 7:21 PM

$ATAI in waves and war is about ibogaine usage for PTSD. $PBM just released news of a breakthrough in high purity ibogaine. The only Nasdaq listed company utilizing nature derived psychedelics

0 · Reply

Tradetime3472 Oct. 14 at 7:03 PM

$PBM “..pharma and large cap biotech have significant capital on hand for M&A — a combined $1 trillion in cash reserves, by some measures.”

0 · Reply

Bubbasoup09 Oct. 13 at 11:23 PM

$PBM 👀

0 · Reply

Market Cap	6.23M
Revenue (ttm)	0.00
Net Income (ttm)	1.01M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	26,600
Avg Vol	705,800
Day's Range	N/A - N/A
Shares Out	1.87M
Stochastic %K	36%
Beta	0.24
Analysts	Strong Buy
Price Target	N/A